Arrowhead Pharmaceuticals (NASDAQ:ARWR) Sets New 1-Year High After Analyst Upgrade
Arrowhead Pharmaceuticals shares (NASDAQ:ARWR) reached a new 52-week high after Leerink Partners raised its price target from $61 to $72 and kept a market perform rating, according to the firm. The stock traded up to $82.48 and last at $81.96. Other analysts cited include RBC ($87), JPMorgan ($88), and Bernstein ($46). The article also notes May 7 earnings: EPS -$0.93 vs -$1.10 expected; revenue $73.74M vs $73.84M.
Analyst target hikes and a fresh 52-week high suggest near-term upside momentum, but the article also highlights recent insider selling and weak recent fundamentals.
Arrowhead Pharmaceuticals hit a new 52-week high after Leerink Partners raised its price target to $72 from $61.
Likely supports continued bullish bias/volatility near-term, but upside may be capped if selling/earnings deterioration reasserts.
Background
The piece is a recap of Arrowhead’s trading move to a new 52-week high alongside multiple recent sell-side rating/price-target changes and insider/institutional activity.
Why it matters
The immediate trading signal is the Leerink price-target increase coinciding with the new high; however, the fundamental backdrop described (large revenue decline, negative profitability) increases the risk that the move fades.
Market relevance
A same-day analyst target increase aligns with a new 52-week high, but the article also flags deteriorating revenue and insider selling—key for traders managing momentum risk.
Market effects
Biotech/clinical-stage RNAi names may see read-across from incremental analyst optimism, but the article’s weak revenue trend tempers broad enthusiasm.
Primarily US small/mid-cap biotech sentiment; limited direct regional spillover beyond NASDAQ biotech complex.
Low—no global deal/regulatory catalyst; mostly sell-side positioning and sentiment.
Alternative perspectives
Despite the upgrade-driven momentum, the article cites sharply declining revenue YoY and multiple sell ratings, which can limit follow-through.
Insider sales (including CFO and other insider transactions) and the negative earnings metrics (negative ROE/net margin, negative P/E) may offset the bullish PT revisions.
Key entities
- companyArrowhead Pharmaceuticals, Inc.
Clinical-stage RNAi biopharmaceutical company whose shares reached a new 52-week high after an analyst target raise.
- analyst_firmLeerink Partners
Raised its price target on ARWR from $61 to $72 (rating: market perform).
- executiveDaniel Joseph Apel
CFO who sold shares under a Rule 10b5-1 plan (tax withholding related to equity vesting).
- executiveJames C. Hamilton
Insider who sold shares under a Rule 10b5-1 plan.
